Clinical trial
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
NCT00036790 · University of Wisconsin, Madison, Other · Completed
Key facts
| NCT number | NCT00036790 |
|---|---|
| Title | Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer |
| Official title | An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer and 3 more |
| Intervention type | Drug |
| Interventions | doxorubicin hydrochloride, motexafin gadolinium |
| Start date | Feb 1, 2002 |
| Primary completion | Oct 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 17, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: